Holen Sie sich die Stockscreener-App
5.88
7.73%
-0.48
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Nuvectis Pharma Grows Its Cash Pile While Chasing Cancer Trials - Finimize
Will Rising Costs Hurt Lancor Holdings Limited’s Margins This YearCurrency Fluctuation Impact & Free High Frequency Trading Ideas - earlytimes.in
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Nuvectis Pharma Doubles Down On R&D Despite Rising Losses - Finimize
Nuvectis Pharma Q3 net loss widens on milestone expenses - MarketScreener
Nuvectis Pharma (NASDAQ: NVCT) posts third quarter results: $7.5M net loss; runway to 3Q-2027 - Stock Titan
Nuvectis Pharma, Inc. SEC 10-Q Report - TradingView
Nuvectis Pharma reveals Q3 2025 financial performance and strategic business updates - Traders Union
Nuvectis Pharma (NASDAQ: NVCT) initiates NXP900 Phase 1b; cash at $35.4M in Q3 results - Stock Titan
What makes Nuvectis Pharma Inc. stock attractive to growth fundsJuly 2025 Setups & Detailed Earnings Play Alerts - newser.com
Does Nuvectis Pharma Inc. qualify in momentum factor screeningMarket Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Nuvectis Pharma Inc a good long term investmentStock Split Announcements & High Yield Market Growth - earlytimes.in
Why Nuvectis Pharma Inc. stock remains undervaluedEarnings Summary Report & Fast Moving Trade Plans - newser.com
Nuvectis Pharma Inc. stock trendline breakdownJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
How strong is Nuvectis Pharma Inc. stock revenue growthJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
How Nuvectis Pharma Inc. stock performs in rate cut cyclesJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.July 2025 Spike Watch & Capital Protection Trading Alerts - newser.com
Predicting Nuvectis Pharma Inc. trend using moving averagesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
What data driven models say about Nuvectis Pharma Inc.’s futureBull Run & Safe Capital Growth Stock Tips - newser.com
Nuvectis Pharma Shares: Poised for Significant Growth? - AD HOC NEWS
Nuvectis Pharma : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener
Insider Buying: Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Acquires 46,900 Shares of Stock - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Purchases $215,459.10 in Stock - MarketBeat
A US$22m Market Cap Boost Pleasing ToNuvectis Pharma Insiders - simplywall.st
What's Driving Renewed Interest In Nuvectis Pharma's Oncology Strategy? - RTTNews
Major Investment Alert: Insider Buys Big in Nuvectis Pharma! - TipRanks
Insider Stock Purchases: October 29, 2025 - Quiver Quantitative
Nuvectis Pharma Stock (NVCT) Opinions on NXP900 Trial Results - Quiver Quantitative
Nuvectis Pharma (NVCT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing - MarketScreener
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
Can Nuvectis Pharma Inc. stock hit analyst price targetsMarket Volume Summary & Daily Technical Forecast Reports - fcp.pa.gov.br
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target By Investing.com - Investing.com South Africa
Can Nuvectis Pharma Inc. stock reach $100 price targetJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - fcp.pa.gov.br
Will Nuvectis Pharma Inc. stock beat EPS estimatesWatch List & Consistent Growth Equity Picks - newser.com
1.11%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):